{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': 'Kungsbron 1, C8',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.29,
 'askSize': 1000,
 'averageDailyVolume10Day': 12137,
 'averageVolume': 71300,
 'averageVolume10days': 12137,
 'beta': 1.327476,
 'beta3Year': None,
 'bid': 23.69,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Stockholm',
 'companyOfficers': [],
 'country': 'Sweden',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.465,
 'dayLow': 23.68,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 916983936,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 21.692,
 'fiftyTwoWeekHigh': 28.38,
 'fiftyTwoWeekLow': 19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 22772865,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 17,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': None,
 'heldPercentInstitutions': None,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/calliditas.se',
 'longBusinessSummary': 'Calliditas Therapeutics AB (publ) operates as a '
                        'biopharmaceutical company in Stockholm, Sweden. It '
                        'focuses on identifying, developing, and '
                        'commercializing pharmaceutical products for patients '
                        "with unmet medical needs. The company's lead product "
                        'candidate is Nefecon, a unique formulation optimized '
                        'to combine a time lag effect with a concentrated '
                        'release of the active substance budesonide, within a '
                        'designated target area. This patented, locally acting '
                        'formulation is intended for treatment of patients '
                        'with the inflammatory renal disease IgA nephropathy. '
                        'Calliditas Therapeutics AB (publ) also intends to '
                        'take Nefecon through a global Phase 3 study to '
                        'commercialization. The company was founded in 2004 '
                        'and is headquartered in Stockholm, Sweden.',
 'longName': 'Calliditas Therapeutics AB (publ)',
 'market': 'us_market',
 'marketCap': 584150400,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': None,
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 24.16,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '46 84 11 30 05',
 'previousClose': 24.08,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -0.29,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.465,
 'regularMarketDayLow': 23.68,
 'regularMarketOpen': 24.16,
 'regularMarketPreviousClose': 24.08,
 'regularMarketPrice': 24.16,
 'regularMarketVolume': 7175,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 23969200,
 'sharesPercentSharesOut': 0.0002,
 'sharesShort': 12445,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Calliditas Therapeutics AB',
 'shortPercentOfFloat': None,
 'shortRatio': 0.05,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'CALT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 21.692,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd7b9e28b-d147-3ca9-9029-b131dd8e88fd',
 'volume': 7175,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.calliditas.se',
 'yield': None,
 'ytdReturn': None,
 'zip': '111 22'}